Akiyama M, Yoshimoto K, Ishigaki S et al (2023) Disease-specific expansion of CD29+IL-17RA+ T effector cells possessing multiple signalling pathways in spondyloarthritis. Rheumatology (Oxford) 62:1296–1305. https://doi.org/10.1093/rheumatology/keac391

Article  PubMed  Google Scholar 

FitzGerald O, Alexis O, Vinod C et al (2021) Psoriatic arthritis (Primer). Nat Rev Dis Primers 7:s41572–s42021. https://doi.org/10.1038/s41572-021-00293-y

Article  Google Scholar 

Baeten D, Sieper J, Braun J et al (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373:2534–2548. https://doi.org/10.1056/NEJMoa1505066

Article  CAS  PubMed  Google Scholar 

Mease PJ, McInnes IB, Kirkham B et al (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373:1329–1339. https://doi.org/10.1056/NEJMoa1412679

Article  CAS  PubMed  Google Scholar 

Mease PJ, Genovese MC, Greenwald MW et al (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370:2295–2306. https://doi.org/10.1056/NEJMoa1315231

Article  CAS  PubMed  Google Scholar 

Wei JC-C, Kim T-H, Kishimoto M et al (2021) Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. Ann Rheum Dis 80:1014–1021. https://doi.org/10.1136/annrheumdis-2020-219406

Article  PubMed  PubMed Central  Google Scholar 

Murakami M, Hagforsen E, Morhenn V et al (2011) Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum: letter to the editor. Exp Dermatol 20:845–847. https://doi.org/10.1111/j.1600-0625.2011.01325.x

Article  CAS  PubMed  Google Scholar 

Okubo Y, Kobayashi S, Murakami M et al (2024) Efficacy and safety of brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, for palmoplantar pustulosis: 16-week results of a randomized clinical trial. Am J Clin Dermatol 25:837–847. https://doi.org/10.1007/s40257-024-00876-x

Article  PubMed  PubMed Central  Google Scholar 

Ikumi N, Fujita H (2025) Effectiveness of brodalumab for guselkumab-resistant pustulotic arthro-osteitis in patients with palmoplantar pustulosis: case series. J Dermatol 52:1869–1873. https://doi.org/10.1111/1346-8138.17964

Article  CAS  PubMed  Google Scholar 

Li Y, Meng F, Jiang H et al (2024) Paradoxical skin lesions induced by IL-17 inhibitors in SAPHO syndrome. J Dermatolog Treat 35:2295239. https://doi.org/10.1080/09546634.2023.2295239

Article  CAS  PubMed  Google Scholar 

Chaitidis N, Papadopoulou Z, Varvara ST et al (2024) Paradoxical psoriasis induced by IL-17 inhibitors: a case series of patients with axial spondyloarthritis and a systematic literature review. Rheumatol Int 44:2659–2668. https://doi.org/10.1007/s00296-024-05647-9

Article  CAS  PubMed  Google Scholar 

Fauny M, Moulin D, D’Amico F et al (2020) Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis 79:1132–1138. https://doi.org/10.1136/annrheumdis-2020-217927

Article  CAS  PubMed  Google Scholar 

Liu K, Sun J (2024) Behcet’s-like disease induced by secukinumab in a patient with psoriasis: a case report and literature review. J Dermatolog Treat 35:2347440. https://doi.org/10.1080/09546634.2024.2347440

Article  CAS  PubMed  Google Scholar 

Lee YH, Song GG (2023) Associations between circulating interleukin-17 levels and Behcet’s disease and between IL-17 gene polymorphisms and disease susceptibility: a meta-analysis. Clin Exp Rheumatol 41:2071–2077. https://doi.org/10.55563/clinexprheumatol/sh84va

Article  PubMed  Google Scholar 

Fagni F, Bettiol A, Talarico R et al (2020) Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre study. Ann Rheum Dis 79:1098–1104. https://doi.org/10.1136/annrheumdis-2020-217108

Article  CAS  PubMed  Google Scholar 

International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080

Google Scholar 

Hatemi G, Mahr A, Ishigatsubo Y et al (2019) Trial of apremilast for oral ulcers in Behçet’s syndrome. N Engl J Med 381:1918–1928. https://doi.org/10.1056/NEJMoa1816594

Article  CAS  PubMed  Google Scholar 

Terui T, Okubo Y, Kobayashi S et al (2025) Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.70166

Article  PubMed  Google Scholar 

Benlidayi IC, Gupta L (2024) Case-based review standards (CABARET): considerations for authors, reviewers, and editors. J Korean Med Sci 39:e225. https://doi.org/10.3346/jkms.2024.39.e225

Article  PubMed  PubMed Central  Google Scholar 

Shiga H, Fukuda S, Iijima K (2017) Interleukin-17A inhibitor-induced Crohn’s disease/Behçet’s disease-like lesions. Inflamm Bowel Dis 23:E38–E39. https://doi.org/10.1097/MIB.0000000000001142

Article  PubMed  Google Scholar 

Barrado-Solís N, Rodrigo-Nicolás B, De la Morena-Barrio I et al (2020) Report of two cases of Behçet’s disease developed during treatment with secukinumab. J Eur Acad Dermatol Venereol 34:e587–e589. https://doi.org/10.1111/jdv.16454

Article  PubMed  Google Scholar 

Ward M, Maliyar K, Gooderham M (2021) A case report of recalcitrant aphthous ulcers in two patients treated with interleukin-17 inhibitors. SAGE Open Med Case Rep 9:2050313X211034925. https://doi.org/10.1177/2050313X211034925

Article  PubMed  PubMed Central  Google Scholar 

Calleja Algarra A, Aragón Miguel R, Andrés Lencina JJ et al (2021) Behçet’s-like disease during secukinumab treatment: new paradoxical reaction? J Dtsch Dermatol Ges 19:116–118. https://doi.org/10.1111/ddg.14196

Article  PubMed  Google Scholar 

Avcı C, Akın G, Akarsu S, Lebe B (2023) Pyoderma gangrenosum and Behçet’s-like disease induced by secukinumab: a paradoxical drug reaction. J Dermatol Treat 34:2235040. https://doi.org/10.1080/09546634.2023.2235040

Article  CAS  Google Scholar 

Dincses E, Yurttas B, Esatoglu SN et al (2019) Secukinumab induced Behçet’s syndrome: a report of two cases. Oxf Med Case Rep 2019:omz041. https://doi.org/10.1093/omcr/omz041

Article  Google Scholar 

Ren Y-K, Ren L, Sun W et al (2025) Paradoxical Behçet’s disease after ixekizumab: a case report and literature review. Indian J Dermatol 70:42–46. https://doi.org/10.4103/ijd.ijd_719_24

Article  PubMed  Google Scholar 

Chen D, Zhou M, Xu A et al (2022) Behcet’s-like disease in a patient treated with Ixekizumab for chronic plaque psoriasis. Scand J Rheumatol 51:336–337. https://doi.org/10.1080/03009742.2021.2014105

Article  CAS  PubMed  Google Scholar 

Ogasawara M, Taniguchi Y (2024) IL-17 inhibitor-induced Behçet-like disease. J Clin Rheumatol 30:e65. https://doi.org/10.1097/RHU.0000000000002025

Article  PubMed  Google Scholar 

Huangfu L, Li R, Huang Y, Wang S (2023) The IL-17 family in diseases: from bench to bedside. Signal Transduct Target Ther 8:402. https://doi.org/10.1038/s41392-023-01620-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gisondi P, Bellinato F (2025) Management of IL-17 inhibitors-induced paradoxical eczema in patients with plaque psoriasis. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.70198

Article  PubMed  PubMed Central  Google Scholar 

Akiyama M, Alshehri W, Suzuki K et